Solitomab (AMG 110) is a bispecific anti-CD3 and anti-epithelial-cell-adhesion-molecule (EpCAM) antibody. Solitomab can be used for the research of primary uterine and ovarian carcinosarcoma cancer. In Vitro Solitomab (1 μg/mL; 4 hours) shows cytotoxicity to EpCAM-positive cell lines and increases the sensibility of EpCAM positive carcinosarcomas (CS) cells to T-cell-cytotoxicity. Solitomab (7 days) increases the expression level of CD25 and HLA-DR protein (T-cell activation markers) on CD8 + and CD4 + T cells. Solitomab (0-2.5 μg/mL; 4 hours) is cytotoxic to ovarian carcinoma cells and the 1 μg/mL dose shows the best tumor killing effects. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Liquid
All
Chemical Reagents
Biomedicine
Organic raw materials
Inorganic chemical industry
intermediate
Agricultural chemicals
Auxiliaries and catalysts
Fragrances and Flavors
Dyes and Pigments
Daily chemical industry
Solitomab
CAS number：1005198-65-1 molecular formula：
overview
compound introduction
Specs
| Chinese alias | 索利托单抗 | ||
| English alias | - | ||
| CAS number | 1005198-65-1 | molecular formula | |
| molecular weight | - | Exact mass | - |
| PSA | - | logp | - |
numbering system
No numbering system information yet
physicochemical properties
No physical and chemical property information yet
Safety information
No safety information yet
Production methods and uses
No production method and use information yet
Related
upstream information
No upstream information yet
downstream information
No downstream information yet
MSDS
Found 0 shareMSDS
